Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24796295 | 0.96 | ATM (0.49) | ATMHPGDSMN1; SMN2LMNAKMT2A | |
| SCHEMBL24795923 | 0.95 | L3MBTL1 (0.44) | ATMHPGDSMN1; SMN2LMNAKMT2A | |
| SCHEMBL24795942 | 0.92 | ATM (0.44) | ATMHPGDSMN1; SMN2LMNAKMT2A | |
| SCHEMBL24796649 | 0.91 | ATM (0.46) | ATMHPGDSMN1; SMN2LMNAKMT2A | |
| SCHEMBL24795945 | 0.88 | ATM (0.41) | ATMHPGDSMN1; SMN2LMNAKMT2A | |
| SCHEMBL21389270 | 0.86 | HPGD (0.44) | ATMHPGDSMN1; SMN2LMNAKMT2A | |
| SCHEMBL24795947 | 0.86 | ATM (0.39) | ATMHPGDSMN1; SMN2LMNAKMT2A | |
| SCHEMBL24796282 | 0.86 | HPGD (0.47) | ATMHPGDSMN1; SMN2LMNAKMT2A | |
| SCHEMBL24796661 | 0.85 | HPGD (0.43) | ATMHPGDSMN1; SMN2LMNAKMT2A | |
| SCHEMBL24796302 | 0.85 | HPGD (0.44) | ATMHPGDSMN1; SMN2LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535660-B1 | Modulators of G-protein coupled receptors | Cannot Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| WO-2019183577-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535660-B1 | Modulators of G-protein coupled receptors | GIPR, GLP1R, GCGR | ATM 4515/4885HPGD 2144/4885SMN1; SMN2 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.